Alprazolam Odt C-Iv

Produces additive CNS depressant effects when coadministered with alprazolam.

Coadministration produces additive CNS depressant effects. Carefully consider pharmacology of agents to be employed.

Produce additive CNS depressant effects when coadministered with alprazolam.

7.6 Drugs and Other Substances Demonstrated to be CYP3A Inhibitors on the Basis of Clinical Studies Involving Benzodiazepines Metabolized Similarly to Alprazolam or on the Basis of In Vitro Studies with Alprazolam or Other Benzodiazepines Use caution during the coadministration of Alprazolam and the following: Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction between alprazolam and the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.

Steady state plasma concentrations increase by approximately 20% when administered concomitantly with alprazolam in doses up to 4 mg/day. Clinical significance unknown.

7.6 Drugs and Other Substances Demonstrated to be CYP3A Inhibitors on the Basis of Clinical Studies Involving Benzodiazepines Metabolized Similarly to Alprazolam or on the Basis of In Vitro Studies with Alprazolam or Other Benzodiazepines Use caution during the coadministration of Alprazolam and the following: Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction between alprazolam and the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.

Coadministration increased alprazolam maximum plasma concentration by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased psychomotor performance.

Steady state plasma concentrations increase by approximately 30% when administered concomitantly with alprazolam in doses up to 4 mg/day. Clinical significance unknown.

Coadministration produces additive CNS depressant effects. Carefully consider pharmacology of agents to be employed.

Coadministration increased alprazolam maximum plasma concentration by 18%, decreased clearance by 22%, and increased half-life by 29%.

Coadministration decreased alprazolam maximum plasma concentration by 6%, decreased clearance by 38%, and increased half-life by 58%.

If alprazolam orally disintegrating tablets are coadministered with other psychotropic agents or anticonvulsant drugs, carefully consider the pharmacology of the agents to be employed, particularly with compounds which might potentiate the action of benzodiazepines. The benzodiazepines, including alprazolam, produce additive CNS depressant effects when coadministered with other psychotropic medications, anticonvulsants, antihistaminics, alcohol and other drugs which themselves produce CNS depression. 7.2 Drugs Effecting Salivary Flow and Stomach pH Because alprazolam orally disintegrating tablets disintegrate in the presence of saliva, and the formulation requires an acidic environment to dissolve, concomitant drugs or diseases that cause dry mouth or raise stomach pH might slow disintegration or dissolution, resulting in slowed or decreased absorption.

Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction between benzodiazepines and the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine [see Warnings and Precautions (5.8)].

Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction between benzodiazepines and the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine [see Warnings and Precautions (5.8)].